Press Release
Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
- Agreement Includes Total Upfront and Milestone Payments of up to
- Akebia to Host Conference Call at
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151214005335/en/
Under the terms of the agreement, MTPC will make payments totaling
"Vadadustat offers a new paradigm for the treatment of anemia for CKD
patients. This partnership with MTPC validates vadadustat's therapeutic
potential and helps ensure that its potential is realized in Asia," said
"A safer treatment for managing anemia related to chronic kidney disease
remains a significant unmet need globally," stated
Conference Call and Webcast
Date: |
|
||
Time: |
|
||
Telephone Access: |
Domestic callers: dial (877) 458-0977 | ||
International callers: dial (484) 653-6724 | |||
Please reference the Akebia conference call | |||
Passcode: 527-4042 | |||
Online Access: |
Go to the Investor Relations section of the Akebia website and
follow |
||
About Vadadustat
Vadadustat is an oral therapy currently in development for the treatment of anemia related to chronic kidney disease (CKD). Vadadustat is designed to stabilize HIF, a transcription factor that regulates the expression of genes involved with red blood cell (RBC) production in response to changes in oxygen levels, by inhibiting the hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzyme. Vadadustat exploits the same mechanism of action used by the body to naturally adapt to lower oxygen availability associated with a moderate increase in altitude. The body responds to lower oxygen availability with increased production of HIF, which coordinates the interdependent processes of iron mobilization and erythropoietin (EPO) production to increase RBC production and, ultimately, improve oxygen delivery.
As a HIF stabilizer with best-in-class potential, vadadustat raises hemoglobin levels predictably and sustainably, with a dosing regimen that allows for a gradual and controlled titration. Vadadustat has been shown to improve iron mobilization, potentially reducing the need for iron supplementation.
About Anemia Related to CKD
Approximately 30 million people in
About
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical
company based in
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements include those about Akebia's strategy, future
plans and prospects, including statements regarding the potential
indications, dosing and benefits of vadadustat, the development plan for
vadadustat, and the expected payments from MTPC to Akebia. The words
"anticipate," "appear," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement, including the risk that existing preclinical
and clinical data may not be predictive of the results of ongoing or
later clinical trials; the funding required to develop vadadustat and
operate the company, and the actual expenses associated therewith; the
cost of the Phase 3 studies of vadadustat and the availability of
financing to cover such costs; the ability of Akebia and MTPC to
successfully complete the clinical development of vadadustat; the timing
and scope of regulatory and reimbursement approvals in
View source version on businesswire.com: http://www.businesswire.com/news/home/20151214005335/en/
Investors:
ejoyce@akebia.com
or
Media:
Eliza@argotpartners.com
or
Investors
/ Media:
Mitsubishi Tanabe Pharma
+81-6-6205-5211
Source:
News Provided by Acquire Media
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax